|01/07/19||Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2018; Company to Present at 37th Annual J.P. Morgan Healthcare Conference|
|AUSTIN, Texas, Jan. 7, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2018 to be approximately $81 million and to exceed $315 million for the full- year ended 2018, near the top of the previously communicated guidance range of $310 to $316 million.
Select fourth quarter highlights include:
Total Licensed Technologies Group revenue grew 23% to more than $41 million, compared to the fourth quarter of 2017
|01/02/19||Luminex Corporation Completes Acquisition of MilliporeSigma's Flow Cytometry Portfolio|
|AUSTIN, Texas, Jan. 2, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio for $75 million in combined stock, asset and inventory purchases. The acquisition is expected to contribute $40 million to $50 million in revenue to Luminex in 2019.
"We are pleased to announce the completion of this transaction and excited to welcome the talented MilliporeSigma flow cytome... |